466 related articles for article (PubMed ID: 28925794)
1. Developments in the formulation and delivery of spray dried vaccines.
Kanojia G; Have RT; Soema PC; Frijlink H; Amorij JP; Kersten G
Hum Vaccin Immunother; 2017 Oct; 13(10):2364-2378. PubMed ID: 28925794
[TBL] [Abstract][Full Text] [Related]
2. Physical and immunogenic stability of spray freeze-dried influenza vaccine powder for pulmonary delivery: comparison of inulin, dextran, or a mixture of dextran and trehalose as protectants.
Murugappan S; Patil HP; Kanojia G; ter Veer W; Meijerhof T; Frijlink HW; Huckriede A; Hinrichs WL
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):716-25. PubMed ID: 23933147
[TBL] [Abstract][Full Text] [Related]
3. Induction of protective immunity against H1N1 influenza A(H1N1)pdm09 with spray-dried and electron-beam sterilised vaccines in non-human primates.
Scherließ R; Ajmera A; Dennis M; Carroll MW; Altrichter J; Silman NJ; Scholz M; Kemter K; Marriott AC
Vaccine; 2014 Apr; 32(19):2231-40. PubMed ID: 24631078
[TBL] [Abstract][Full Text] [Related]
4. A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation.
Saluja V; Amorij JP; Kapteyn JC; de Boer AH; Frijlink HW; Hinrichs WL
J Control Release; 2010 Jun; 144(2):127-33. PubMed ID: 20219608
[TBL] [Abstract][Full Text] [Related]
5. Spray-Dried Influenza Antigen with Trehalose and Leucine Produces an Aerosolizable Powder Vaccine Formulation that Induces Strong Systemic and Mucosal Immunity after Pulmonary Administration.
Sou T; Morton DA; Williamson M; Meeusen EN; Kaminskas LM; McIntosh MP
J Aerosol Med Pulm Drug Deliv; 2015 Oct; 28(5):361-71. PubMed ID: 25714115
[TBL] [Abstract][Full Text] [Related]
6. Designing CAF-adjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of CAF01.
Ingvarsson PT; Schmidt ST; Christensen D; Larsen NB; Hinrichs WL; Andersen P; Rantanen J; Nielsen HM; Yang M; Foged C
J Control Release; 2013 May; 167(3):256-64. PubMed ID: 23415813
[TBL] [Abstract][Full Text] [Related]
7. Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on Stability II: stability of a vaccine.
Abdul-Fattah AM; Truong-Le V; Yee L; Pan E; Ao Y; Kalonia DS; Pikal MJ
Pharm Res; 2007 Apr; 24(4):715-27. PubMed ID: 17372697
[TBL] [Abstract][Full Text] [Related]
8. Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application.
Maa YF; Zhao L; Payne LG; Chen D
J Pharm Sci; 2003 Feb; 92(2):319-32. PubMed ID: 12532382
[TBL] [Abstract][Full Text] [Related]
9. Stabilization of Live Attenuated Influenza Vaccines by Freeze Drying, Spray Drying, and Foam Drying.
Lovalenti PM; Anderl J; Yee L; Nguyen V; Ghavami B; Ohtake S; Saxena A; Voss T; Truong-Le V
Pharm Res; 2016 May; 33(5):1144-60. PubMed ID: 26818839
[TBL] [Abstract][Full Text] [Related]
10. Influenza vaccine powder formulation development: spray-freeze-drying and stability evaluation.
Maa YF; Ameri M; Shu C; Payne LG; Chen D
J Pharm Sci; 2004 Jul; 93(7):1912-23. PubMed ID: 15176078
[TBL] [Abstract][Full Text] [Related]
11. Spray drying TB vaccines for pulmonary administration.
Fourie PB; Germishuizen WA; Wong YL; Edwards DA
Expert Opin Biol Ther; 2008 Jul; 8(7):857-63. PubMed ID: 18564902
[TBL] [Abstract][Full Text] [Related]
12. A Design of Experiment approach to predict product and process parameters for a spray dried influenza vaccine.
Kanojia G; Willems GJ; Frijlink HW; Kersten GF; Soema PC; Amorij JP
Int J Pharm; 2016 Sep; 511(2):1098-111. PubMed ID: 27523619
[TBL] [Abstract][Full Text] [Related]
13. Stability of lyophilized and spray dried vaccine formulations.
Preston KB; Randolph TW
Adv Drug Deliv Rev; 2021 Apr; 171():50-61. PubMed ID: 33484735
[TBL] [Abstract][Full Text] [Related]
14. Spray drying and vaccine stabilization.
McAdams D; Chen D; Kristensen D
Expert Rev Vaccines; 2012 Oct; 11(10):1211-9. PubMed ID: 23176654
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the effects of spray drying parameters for producing cubosome powder precursors.
von Halling Laier C; Sonne Alstrøm T; Travers Bargholz M; Bjerg Sjøltov P; Rades T; Boisen A; Nielsen LH
Eur J Pharm Biopharm; 2019 Feb; 135():44-48. PubMed ID: 30576708
[TBL] [Abstract][Full Text] [Related]
16. Manufacturing of High-Concentration Monoclonal Antibody Formulations via Spray Drying-the Road to Manufacturing Scale.
Gikanga B; Turok R; Hui A; Bowen M; Stauch OB; Maa YF
PDA J Pharm Sci Technol; 2015; 69(1):59-73. PubMed ID: 25691715
[TBL] [Abstract][Full Text] [Related]
17. Dry influenza vaccines: towards a stable, effective and convenient alternative to conventional parenteral influenza vaccination.
Tomar J; Born PA; Frijlink HW; Hinrichs WL
Expert Rev Vaccines; 2016 Nov; 15(11):1431-1447. PubMed ID: 27118428
[TBL] [Abstract][Full Text] [Related]
18. Spray drying technique: II. Current applications in pharmaceutical technology.
Sollohub K; Cal K
J Pharm Sci; 2010 Feb; 99(2):587-97. PubMed ID: 19862804
[TBL] [Abstract][Full Text] [Related]
19. Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination.
Garmise RJ; Staats HF; Hickey AJ
AAPS PharmSciTech; 2007 Oct; 8(4):E81. PubMed ID: 18181542
[TBL] [Abstract][Full Text] [Related]
20. Stabilization of HAC1 influenza vaccine by spray drying: formulation development and process scale-up.
Zhu C; Shoji Y; McCray S; Burke M; Hartman CE; Chichester JA; Breit J; Yusibov V; Chen D; Lal M
Pharm Res; 2014 Nov; 31(11):3006-18. PubMed ID: 24858396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
